The NH₂-Terminal Coiled-Coil Domain and Tyrosine 177 Play Important Roles in Induction of a Myeloproliferative Disease in Mice by Bcr-Abl

REFERENCES

• Afar, D. E., A. Goga, J. McLaughlin, O. N. Witte, and C. L. Sawyers. 1994. Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264:424–426.
   PubMed Web of Science ®Google Scholar
• Bai, R. Y., T. Jahn, S. Schrem, G. Munzert, K. M. Weidner, J. Y. Wang, and J. Duyster. 1998. The SH2-containing adapter protein GRB10 interacts with BCR-ABL. Oncogene 17:941–948.
   PubMed Web of Science ®Google Scholar
• Carlesso, N., D. A. Frank, and J. D. Griffin. 1996. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 183:811–820.
   PubMed Web of Science ®Google Scholar
• Carron, C., F. Cormier, A. Janin, V. Lacronique, M. Giovannini, M. T. Daniel, O. Bernard, and J. Ghysdael. 2000. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95:3891–3899.
   PubMed Web of Science ®Google Scholar
• Cortez, D., L. Kadlec, and A. M. Pendergast. 1995. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15:5531–5541.
   PubMed Web of Science ®Google Scholar
• Daley, G. Q., R. A. Van Etten, and D. Baltimore. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830.
   PubMed Web of Science ®Google Scholar
• Daley, G. Q., R. A. Van Etten, P. K. Jackson, A. Bernards, and D. Baltimore. 1992. Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol. Cell. Biol. 12:1864–1871.
   PubMed Web of Science ®Google Scholar
• Elefanty, A. G., and S. Cory. 1992. Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions. Mol. Cell. Biol. 12:1755–1763.
   PubMed Web of Science ®Google Scholar
• Elefanty, A. G., I. K. Hariharan, and S. Cory. 1990. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9:1069–1078.
   PubMed Web of Science ®Google Scholar
• Faderl, S., M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, and H. M. Kantarjian. 1999. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341:164–172.
   PubMed Web of Science ®Google Scholar
• Franz, W. M., P. Berger, and J. Y. Wang. 1989. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8:137–147.
   PubMed Web of Science ®Google Scholar
• Goga, A., J. McLaughlin, D. E. Afar, D. C. Saffran, and O. N. Witte. 1995. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981–988.
   PubMed Web of Science ®Google Scholar
• Golub, T. R., A. Goga, G. F. Barker, D. E. Afar, J. McLaughlin, S. K. Bohlander, J. D. Rowley, O. N. Witte, and D. G. Gilliland. 1996. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol. Cell. Biol. 16:4107–4116.
   PubMed Web of Science ®Google Scholar
• Gross, A. W., X. Zhang, and R. Ren. 1999. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol. Cell. Biol. 19:6918–6928.
   PubMed Web of Science ®Google Scholar
• Hao, S. X., and R. Ren. 2000. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol. Cell. Biol. 20:1149–1161.
   PubMed Web of Science ®Google Scholar
• Heisterkamp, N., G. Jenster, J. ten Hoeve, D. Zovich, P. K. Pattengale, and J. Groffen. 1990. Acute leukemia in bcr/abl transgenic mice. Nature 344:251–253.
   PubMed Web of Science ®Google Scholar
• Honda, H., T. Fujii, M. Takatoku, H. Mano, O. N. Witte, Y. Yazaki, and H. Hirai. 1995. Expression of p210bcr-abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood 85:2853–2861.
   PubMed Web of Science ®Google Scholar
• Honda, H., H. Oda, T. Suzuki, T. Takahashi, O. N. Witte, K. Ozawa, T. Ishikawa, Y. Yazaki, and H. Hirai. 1998. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood 91:2067–2075.
   PubMed Web of Science ®Google Scholar
• Honda, H., T. Ushijima, K. Wakazono, H. Oda, Y. Tanaka, S. Aizawa, T. Ishikawa, Y. Yazaki, and H. Hirai. 2000. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 95:1144–1150.
   PubMed Web of Science ®Google Scholar
• Huettner, C. S., P. Zhang, R. A. Van Etten, and D. G. Tenen. 2000. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24:57–60.
   PubMed Web of Science ®Google Scholar
• Jackson, P., and D. Baltimore. 1989. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8:449–456.
   PubMed Web of Science ®Google Scholar
• Kelliher, M. A., J. McLaughlin, O. N. Witte, and N. Rosenberg. 1990. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87:6649–6653 (Erratum, 87:9072.)
   PubMed Web of Science ®Google Scholar
• Kurzrock, R., J. U. Gutterman, and M. Talpaz. 1988. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319:990–998.
   PubMed Web of Science ®Google Scholar
• Li, S., R. L. Ilaria Jr., R. P. Million, G. Q. Daley, and R. A. Van Etten. 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189:1399–1412.
   PubMed Web of Science ®Google Scholar
• Liu, J., M. Campbell, J. Q. Guo, D. Lu, Y. M. Xian, B. S. Andersson, and R. B. Arlinghaus. 1993. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. Oncogene 8:101–109 (Erratum, 8:2021.)
   PubMed Web of Science ®Google Scholar
• Liu, J., Y. Wu, G. Z. Ma, D. Lu, L. Haataja, N. Heisterkamp, J. Groffen, and R. B. Arlinghaus. 1996. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol. Cell. Biol. 16:998–1005.
   PubMed Web of Science ®Google Scholar
• Lowenstein, E. J., R. J. Daly, A. G. Betzer, W. Li, B. Margolis, R. Lammers, A. Ullrich, E. Y. Skolnick, D. Bar-Sagi, and J. Schlessinger. 1992. The SH2 and SH3 domains containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70:431–442.
   PubMed Web of Science ®Google Scholar
• Maru, Y., O. N. Witte, and M. Shibuya. 1996. Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence. FEBS Lett. 379:244–246.
   PubMed Web of Science ®Google Scholar
• Mayer, B. J., and D. Baltimore. 1994. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. Mol. Cell. Biol. 14:2883–2894.
   PubMed Web of Science ®Google Scholar
• McWhirter, J. R., D. L. Galasso, and J. Y. Wang. 1993. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13:7587–7595.
   PubMed Web of Science ®Google Scholar
• McWhirter, J. R., and J. Y. Wang. 1991. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 11:1553–1565.
   PubMed Web of Science ®Google Scholar
• McWhirter, J. R., and J. Y. Wang. 1997. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene 15:1625–1634.
   PubMed Web of Science ®Google Scholar
• Melo, J. V.. 1997. BCR-ABL gene variants. Baillieres Clin. Haematol. 10:203–222.
   PubMed Web of Science ®Google Scholar
• Million, R. P., and R. A. Van Etten. 2000. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96:664–670.
   PubMed Web of Science ®Google Scholar
• Muller, A. J., J. C. Young, A. M. Pendergast, M. Pondel, N. R. Landau, D. R. Littman, and O. N. Witte. 1991. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol. Cell. Biol. 11:1785–1792.
   PubMed Web of Science ®Google Scholar
• Papadopoulos, P., S. A. Ridge, C. A. Boucher, C. Stocking, and L. M. Wiedemann. 1995. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res. 55:34–38.
   PubMed Web of Science ®Google Scholar
• Pear, W. S., J. P. Miller, L. Xu, J. C. Pui, B. Soffer, R. C. Quackenbush, A. M. Pendergast, R. Bronson, J. C. Aster, M. L. Scott, and D. Baltimore. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780–3792.
   PubMed Web of Science ®Google Scholar
• Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392–8396.
   PubMed Web of Science ®Google Scholar
• Pendergast, A. M., L. A. Quilliam, L. D. Cripe, C. H. Bassing, Z. Dai, N. Li, A. Batzer, K. M. Rabun, C. J. Der, J. Schlessinger, et al.. 1993. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175–185.
   PubMed Web of Science ®Google Scholar
• Puil, L., J. Liu, G. Gish, G. Mbamalu, D. Bowtell, P. G. Pelicci, R. Arlinghaus, and T. Pawson. 1994. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13:764–773.
   PubMed Web of Science ®Google Scholar
• Raitano, A. B., Y. E. Whang, and C. L. Sawyers. 1997. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta 1333:F201–F216.
   PubMed Web of Science ®Google Scholar
• Ren, R., Z. S. Ye, and D. Baltimore. 1994. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev. 8:783–795.
   PubMed Web of Science ®Google Scholar
• Sawyers, C. L.. 1999. Chronic myeloid leukemia. N. Engl. J. Med. 340:1330–1340.
   PubMed Web of Science ®Google Scholar
• Tauchi, T., S. Okabe, K. Miyazawa, and K. Ohyashiki. 1998. The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells. Int. J. Oncol. 12:1269–1276.
   PubMed Web of Science ®Google Scholar
• Tomasson, M. H., D. W. Sternberg, I. R. Williams, M. Carroll, D. Cain, J. C. Aster, R. L. Ilaria Jr., R. A. Etten, and D. G. Gilliland. 2000. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J. Clin. Investig. 105:423–432.
   PubMed Web of Science ®Google Scholar
• Verfaillie, C. M., R. Hurley, B. I. Lundell, C. Zhao, and R. Bhatia. 1997. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?. Acta Haematol. 97:40–52.
   PubMed Web of Science ®Google Scholar
• Voncken, J. W., V. Kaartinen, P. K. Pattengale, W. T. Germeraad, J. Groffen, and N. Heisterkamp. 1995. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603–4611.
   PubMed Web of Science ®Google Scholar
• Wootton, J. C.. 1994. Non-globular domains in protein sequences: automated segmentation using complexity measures. Comput. Chem. 18:269–285.
   PubMedGoogle Scholar
• Wu, Y., J. Liu, and R. B. Arlinghaus. 1998. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene 16:141–146.
   PubMed Web of Science ®Google Scholar
• Zhang, X., and R. Ren. 1998. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92:3829–3840.
   PubMed Web of Science ®Google Scholar